tbuckley/cabot-search huggingface dataset:
Pentamidine and Hypoglycemia
Authors: STEVEN M. SHARPE
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 July 1983Pentamidine and HypoglycemiaSTEVEN M. SHARPE, M.D.STEVEN M. SHARPE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-99-1-128_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Symptomatic hypoglycemia is an important potential complication of pentamidine therapy. A warning is timely because many physicians may consider using pentamidine for patients with the acquired immunodeficiency syndrome who develop Pneumocystis carinii infections.A 20-year-old Haitian woman was transferred to the George Washington University Hospital with a 6-month history of diarrhea and a 3-day history of fever and pulmonary infiltrates. Trimethoprim and sulfamethaxozole, along with other antibiotic agents, were started at the time of admission. The next morning an open lung biopsy was done which showedP. cariniipneumonia. Only trimethoprim and sulfamethoxazole were then continued. Because...References1. KLINKHAMER L. Hypoglycemia during pentamidine treatment for trypanosomiasis. Trop Geophys Med. 1958;10:332-6. MedlineGoogle Scholar2. WANGFREEMANGARTASINKS JAJL. Unusual complications of pentamidine in the treatment of pneumocystis carinii pneumonia. Pediatr Pharmacol Therap. 1970;77:311-4. Google Scholar3. COLLOMBMILETTOLEVRON HGM. Troubles de la glycoregulation et diamidines. Med Trop. 1956;16:786-94. Google Scholar4. BARTATOTHKOSNAISZALNOKI LMIJ. Lebensbedrohliche Hypoglykämie unter Pentamidinbehandlung. Kindenarztliche Praxis. 1974;3:131-4. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: The George Washington University Hospital Washington, DC 20037 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySulfonamides, sulfadiazine, trimethoprim-sulfamethoxazole, pentamidine, pyrimethamine, dapsone, quinolonesSulfonamides, sulfadiazine, trimethoprim-sulfamethoxazole, pentamidine, pyrimethamine, dapsone, quinolonesMiscellaneous drugs with nephrotoxic potential (Sulfonamides, sulfadiazine, trimethoprim-sulfamethoxazole, pentamidine, pyrimethamine, dapsone, quinolones)Hypoglycemic coma from pentamadine in an AIDS patientPentamidine and HypoglycemiaOM P. GANDA, M.D.Diagnosis and treatment of ‘insulinoma’Pentamidine and HypoglycemiaJOHN K. MURDOCH, B.SC.PHM., JAY S. KEYSTONE, M.D. 1 July 1983Volume 99, Issue 1Page: 128-128KeywordsAIDSAntibioticsBiopsyDiarrheaFeversHypoglycemiaLungsPneumocystisPneumonia Issue Published: 1 July 1983 PDF DownloadLoading ...
D7-06: Open Non-randomised Phase II Pilot Study of Neoadjuvant Cetuximab in combination with Cisplatin and Gemcitabine in patients with resectable Non-small Cell Lung Cancer
Authors: Linda E. Coate, Sinead Cuffe, Dermot McDowell, Kathy Gately, Martin Barr, James Meaney, Finbar O’Connell, Siobhan Nicholson, Vincent Young, Kenneth O’Byrne
Journal: Journal of Thoracic Oncology (2007)
Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNFα regulation and proliferation of hematopoietic progenitor cells
Authors: Paula Río, Xabier Agirre, Leire Garate, Rocío Baños, Lara Álvarez, Edurne San José-Enériz, Isabel Badell, José A. Casado, Marina Garín, Felipe Prósper, Juan A. Bueren
Journal: Blood (2012)
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION
Authors: AlessandroM. Gianni, Marco Bregni, AngelikaC. Stern, Salvatore Siena, Corrado Tarella, Alessandro Pileri, Gianni Bonadonna
Journal: The Lancet (1989)
F-18 Fluorodeoxyglucose Positron Emission Tomographic Imaging of Cytomegalovirus Pneumonia
Authors: Gavin C. Mackie
Journal: Clinical Nuclear Medicine (2004)

FDG is commonly used to evaluate neoplastic disorders, but it is well-known that activity may also occur in infectious and inflammatory disorders. A case of cytomegalovirus pneumonia detected by FDG PET in an immunocompromised patient is presented. The FDG PET findings were incidental in a patient with a history of natural killer T-cell non-Hodgkin lymphoma presenting for disease staging. Subsequent In-111-labeled leukocyte scintigraphy and CT supported the diagnosis of an opportunistic infection, which was later confirmed by viral culture.
Validation of the Fresno test of competence in evidence based medicine
Authors: K. D Ramos
Journal: BMJ (2003)

To describe the development and validation of a test of knowledge and skills in evidence based medicine.Cross sectional study.Family practice residency programme in California; a list server for those who teach evidence based medicine; and an evidence based medicine seminar series.Family practice residents and faculty members (n=43); volunteers self identified as experts in evidence based medicine (n=53); family practice teachers (19) beginning a seminar series on evidence based medicine.The Fresno test is a performance based measure for use in medical education that assesses a wide range of evidence based medicine skills. Open ended questions are scored with standardised grading rubrics. Calculation skills are assessed by fill in the blank questions.Inter-rater reliability, internal reliability, item analyses, and construct validity.Inter-rater correlations ranged from 0.76 to 0.98 for individual items. Cronbach's alpha was 0.88. Item difficulties ranged from moderate to difficult, all with positive and strong ability to discriminate between candidates. Experts scored consistently higher than novices. On the 212 point test, the novice mean was 95.6 and the expert mean was 147.5 (P<0.001). On individual items, a higher proportion of experts than novices earned passing scores on 15 of the 17 items.The Fresno test is a reliable and valid test for detecting the effect of instruction in evidence based medicine. Its use in other settings requires further exploration.
Inadvertent Administration of Intravenous Fluids Contaminated with Fungus
Authors: JEFFREY A. DAISY
Journal: Annals of Internal Medicine (1979)

We present here the case of a patient inadvertently infused with intravenous fluid containing a "fungus ball." Because little is known about such cases, we surveyed 113 infectious diseases specialists for their experiences and ideas on management. Seventy-six responded, of whom 18 had seen a total of 24 cases. Intravenous-fluid containers were often defective, and the fungi involved were usually "contaminants." One patient developed significant fungal infection, and six others had transient symptoms temporally related to the infusion. Most specialists would administer antifungal therapy if symptoms developed, the patient was immunocompromised, or the fungus was pathogenic for humans.
Anti-Glaxo campaign heats up in United States
Authors: R. Moynihan
Journal: BMJ (2003)

Pharmaceutical giant GlaxoSmithKline is facing a growing backlash over its decision to cut supplies to Canadian pharmacies selling cheap drugs into the United States.

In recent years elderly Americans have been making much publicised bus trips across the border and using online pharmacies to buy drugs from Canada, where they cost anything from half to a sixth the price in the United States.

In late January GlaxoSmithKline announced it was suspending sales to Canadian wholesalers and pharmacies that exported drugs to prevent what it described as “illegal, potentially unsafe …
Abstract 4479: Antiplatelet Therapy and Stent Thrombosis after Sirolimus-Eluting Stent Implantation
Authors: Takeshi Kimura, Takeshi Morimoto, Yoshihisa Nakagawa, Toshihiro Tamura, Kazushige Kadota, Hitoshi Yasumoto, Hideo Nishikawa, Yoshikazu Hiasa, Toshiya Muramatsu, Taiichiro Meguro, Yasuhiko Hayashi, Shunichi Miyazaki, Shigeru Oshima, Takashi Honda, Nobuo Shiode, Masanobu Namura, Takahito Sone, Masakiyo Nobuyoshi, Toru Kita, Kazuaki Mitsudo
Journal: Circulation (2008)

Influences of antiplatelet therapy discontinuation on clinical outcomes after drug-eluting stent implantation are not adequately addressed yet. In an observational study in Japan, two-year outcomes...
A reexamination of the role of LYT-2-positive T cells in murine skin graft rejection.
Authors: L LeFrancois, M J Bevan
Journal: The Journal of Experimental Medicine (1984)

We have investigated which T cell subclass defined by cytolysis with monoclonal anti-Lyt-1.2 and anti-Lyt-2.2 antibodies is required to adoptively transfer the ability to reject skin grafts. B6.Thy-1.1 spleen cells immune to graft antigens were fractionated with antibody plus C' and transferred to adult thymectomized, irradiated, bone marrow-reconstituted (ATXBM) B6.Thy-1.2 hosts that were simultaneously grafted with BALB.B skin. We found that when the ATXBM hosts were used 6 wk after irradiation and marrow reconstitution, both Lyt-1-depleted and Lyt-2-depleted immune spleen cells could transfer the ability to promptly reject skin grafts. However, such ATXBM recipients of Lyt-2-depleted cells that had rejected skin grafts were found to contain graft-specific CTL that were largely of host (B6.Thy-1.2) origin. When ATXBM hosts were used for the experiment 1 wk after irradiation and marrow reconstitution, no host-derived graft-specific CTL could be detected. However, graft rejection occurred in recipients of anti-Lyt-1- or anti-Lyt-2 plus C'-treated immune cells and specific CTL were generated from spleen cells of both groups. Thus, in the absence of a host-derived response, adoptively transferred immune Lyt-2+ cells, either resistant to, or that escaped from, antibody plus C' treatment, are able to expand in response to the antigenic stimulus provided by the graft. A more complete elimination of specific T cell subclasses is therefore needed to assess the relative contribution of a particular subset to the graft rejection process.
One small step for paraplegics, a giant leap for bioengineering
Authors: Bruce B. Dan
Journal: JAMA (1983)

In what may be one of the most unusual spin-offs of antisubmarine warfare technology, investigators at Chicago's Illinois Institute of Technology (IIT) and Michael Reese Medical Center are enabling paraplegics to walk again. Daniel Graupé, PhD, professor of electrical engineering and head of the signal processing and biomedical systems laboratory at IIT, and Kate H. Kohn, MD, chair of the rehabilitation department at Michael Reese, have collaborated to make it possible for patients with complete transection of the spinal cord to sit, stand, and walk under their own control. This seemingly impossible feat has been accomplished by capturing and interpreting myoelectric signals from above the level of the spinal cord injury and transmitting them to the paralyzed muscles below—in effect detouring around the lesion. So far, in preliminary trials, the technique has been used successfully with five paraplegics—two in the United States and three in Israel. More patients, of course,
Metallothionein in rabbit kidneys preserved for transplantation.
Authors: C G Elinder, G Lundgren, M Nordberg, B Palm, M Piscator
Journal: Environmental Health Perspectives (1984)

Thirteen rabbits were given repeated cadmium injections to achieve cadmium concentrations in kidney cortex ranging from 0.05 to 1 mmole Cd/kg wet weight. Another four animals served as controls. One kidney from each animal was frozen directly to -70 degrees C whereas the other kidney was kept for 24 hr at +4 degrees C in a preservative (Sachs' solution) to simulate conditions for preservation of human donor kidneys before transplantation. Protein binding of cadmium, zinc and copper in kidney homogenates and the concentration of metallothionein (MT) were measured in the kidney that was frozen directly and in the kidney that had been preserved. No gross differences in either the protein binding of cadmium, zinc and copper or in the MT content were seen between the directly frozen and preserved kidneys from the same animal. This indicates that MT is not rapidly broken down in rabbit kidneys which have been preserved similarly to human donor kidneys for 24 hr in a standard preservative solution prior to a transplantation.
Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.
Authors: O Sartor, C A McLellan, C E Myers, M M Borner
Journal: Journal of Clinical Investigation (1992)

Suramin, a synthetic polysulfonated anionic compound, is known to abrogate the activity of a variety of growth factors that serve as ligands for receptor-class protein-tyrosine kinases. Based on this information, we initially hypothesized that suramin treatment would be associated with decreased tyrosine phosphorylation. Upon testing this hypothesis in prostate cancer cell lines, we found that the most conspicuous effect of suramin was to increase the tyrosine phosphorylation of several distinct proteins. Further analyses indicate that suramin-induced increases in tyrosine phosphorylation represent a generalized, but not universal, phenomenon found in cell lines derived from a variety of human tissues. These rapid and specific suramin-induced alterations represent a novel finding for a non-polypeptide pharmaceutical agent and question the hypothesis that suramin exerts its antitumor action simply by abrogation of growth factor action.
Appetite and Cancer-Associated Anorexia: A Review
Authors: Mellar P. Davis, Robert Dreicer, Declan Walsh, Ruth Lagman, Susan B. LeGrand
Journal: Journal of Clinical Oncology (2004)

Appetite is governed by peripheral hormones and central neurotransmitters that act on the arcuate nucleus of the hypothalamus and nucleus tactus solitarius of the brainstem. Cancer anorexia appears to be the result of an imbalance between neuropeptide-Y and pro-opiomelanocortin signals favoring pro-opiomelanocortin. Many of the appetite stimulants redress this imbalance. Most of our understanding of appetite neurophysiology and tumor-associated anorexia is derived from animals and has not been verified in humans. There have been few clinical trials and very little translational research on anorexia despite its prevalence in cancer.
Abstract 1249: Potent immunomodulatory effects of lenalidomide enhance the effect of a therapeutic vaccine against established lymphoma in mice .
Authors: Ippei Sakamaki, Larry W. Kwak, Soung-chul Cha, Qing Yi, Beatrisa Lerman, Jian Chen, Sekhar Surapaneni, Scott Bateman, Hong Qin
Journal: Cancer Research (2013)

Abstract Lenalidomide is an effective therapeutic agent with direct inhibitory effects on malignant B- and plasma cells and immunomodulatory effects on the T cell activation. The dual function of lenalidomide makes it an appealing candidate for combination with other novel cancer agents. We investigated the immune stimulatory effects of lenalidomide, administrated to mice in doses which provided comparable pharmacokinetics to human patients, on the potency of a novel fusion DNA lymphoma vaccine. The combination protected mice from lethal challenge with syngeneic A20 murine lymphoma, resulting in significantly improved survival compared with vaccine or lenalidomide alone and induced immune memory. In vivo depletion experiments demonstrated a requirement for effector CD8+ and CD4+ T cells. Surprisingly, lenalidomide alone was associated with reduced numbers of systemic immune suppressive cells (MDSC/Treg) in tumor-bearing, but not naïve mice, an effect that was independent of simple tumor burden reduction. Finally, the combination of lenalidomide and vaccine produced significantly improved survival in mice with 7 day established tumors. These results demonstrated the dual effect of lenalidomide on enhancing antigen-specific T-cell immunity and a novel mechanism of action reversing tumor-induced immune suppression, which makes it ideal for combination with vaccines as an immune adjuvant. Citation Format: Ippei Sakamaki, Larry W. Kwak, Soung-chul Cha, Qing Yi, Beatrisa Lerman, Jian Chen, Sekhar Surapaneni, Scott Bateman, Hong Qin. Potent immunomodulatory effects of lenalidomide enhance the effect of a therapeutic vaccine against established lymphoma in mice . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1249. doi:10.1158/1538-7445.AM2013-1249
Autoimmune sera reactive with Sm antigen contain high levels of RNP-like antibodies.
Authors: W H Reeves, D E Fisher, R G Lahita, H G Kunkel
Journal: Journal of Clinical Investigation (1985)

Ribonucleoprotein particles containing Sm antigen were separated from particles containing both Sm and RNP antigens by ion-exchange chromatography to study the recognition of these antigens by autoimmune sera. By using the separated antigens, anti-Sm and/or anti-RNP antibodies were detected in approximately 60% of sera from systemic lupus erythematosus patients by both enzyme-linked immunosorbent assay and immunoprecipitation of radiolabeled antigens followed by analysis on sodium dodecyl sulfate-polyacrylamide gels. These antibodies were detected in 30% of the same sera using the standard passive hemagglutination technique. Competition experiments demonstrated that all of the sera tested that contained anti-Sm antibodies also had anti-RNP-like reactivity. This latter reactivity usually represented 80% or more of the total Sm and RNP binding activity in lupus sera. The binding to RNP-like determinants by several of the sera was uniquely resistant to treatment of the antigen with snake venom exonuclease. These studies indicate that humoral immunity against Sm and RNP antigens in systemic lupus erythematosus is directed primarily against a single type of ribonucleoprotein particle in which the two antigens are physically associated. The specific binding to a single type of ribonucleoprotein particle suggests that this particle may be especially immunogenic and that it might play an important role in induction of the humoral immune response to Sm and RNP.
The Physician-Computer Connection: A Practical Guide to Physician Involvement in Hospital Information Systems
Authors: S. Satya-Murti
Journal: JAMA (1993)

Hospital information systems are computerized information banks that deal with patient-related data. Typically they contain demographics, medical information—history, diagnosis, laboratory findings—and financial information. They may link with physician offices also. While every hospital nowadays uses an information system of some type, a truly integrated and sophisticated system inclusive of almost all aspects of patient care is uncommon. It should provide facilities for electronic order writing at the nurse's station, telephone retrieval of laboratory data from a physician's office, inpatient and outpatient record entry and retrieval, and a database for clinical research. The authors of<i>The Physician-Computer Connection</i>are veterans at the art of establishing hospital information systems in more than one hospital. They describe their collective experience in this short and readable book. An active clinician and a hospital administrator pursue the same vocational goal, although overt expression of such shared aims is generally muted, even at staff and committee
PTU-077 Diagnostic Potential of Volatile Organic Compounds as Urine Biomarkers in Inflammatory Bowel Disease
Authors: H Jayasena, T Khalid, C S Probert
Journal: Gut (2013)

<h3>Introduction</h3> The potential of urinary VOCs as biomarkers in IBD is unknown. <h3>Methods</h3> Patients recruited from outpatient clinic, with proven Crohn’s disease (CDN = 35) and ulcerative colitis (UC N = 49), IBS (N = 22) and 41 healthy volunteers. Concurrent disease activity was recorded using Harvey-Bradshaw index (HBI) in CD and simple clinical colitis activity index (SCCAI) in UC. Urine headspace gas was sampled using SPME and was transferred to GCMS for VOC identification. <h3>Results</h3> <h3>Conclusion</h3> Urine VOCs are capable of distinguishing IBD from IBS. <h3>Disclosure of Interest</h3> None Declared
The Enigma of Drug-Eluting Stents
Authors: Robert A. Harrington, E. Magnus Ohman
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Efficacy of Antidepressants on Overall Well-Being and Self-Reported Depression Symptom Severity in Youth: A Meta-Analysis
Authors: Glen I. Spielmans, Katherine Gerwig
Journal: Psychotherapy and Psychosomatics (2014)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Recent meta-analyses of the efficacy of second-generation antidepressants for youth have concluded that such drugs possess a statistically significant advantage over placebo in terms of clinician-rated depressive symptoms. However, no meta-analysis has included measures of quality of life, global mental health, self-esteem, or autonomy. Further, prior meta-analyses have not included self-reports of depressive symptoms. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Studies were selected through searching Medline, PsycINFO, and the Cochrane Central Register for Controlled Trials databases as well as GlaxoSmithKline's online trial registry. We included self-reports of depressive symptoms and pooled measures of quality of life, global mental health, self-esteem, and autonomous functioning as a proxy for overall well-being. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We found a nonsignificant difference between second-generation antidepressants and placebo in terms of self-reported depressive symptoms (k = 6 trials, g = 0.06, p = 0.36). Further, pooled across measures of quality of life, global mental health, self-esteem, and autonomy, antidepressants yielded no significant advantage over placebo (k = 3 trials, g = 0.11, p = 0.13). &lt;b&gt;&lt;i&gt;Discussion:&lt;/i&gt;&lt;/b&gt; Though limited by a small number of trials, our analyses suggest that antidepressants offer little to no benefit in improving overall well-being among depressed children and adolescents.